Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis

(2021) Loretah Chibaya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GSK3B induces autophagy by phosphorylating ULK1

(2021) Hye Young Ryu et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma

(2021) Hyuk Moon et al.   Cancers

Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review)

(2021) Shaojie Yang et al.   Frontiers in Oncology

The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target

(2020) Si-Tu Xue et al.   Autophagy

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

Molecular therapies for HCC: Looking outside the box

(2020) Sandrine Faivre et al.   JOURNAL OF HEPATOLOGY

High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma

(2020) Shu‑Shu Song et al.   Oncology Letters

What turns CREB on? And off? And why does it matter?

(2020) André Steven et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma

(2020) Yuan-Deng Luo et al.   JOURNAL OF HEPATOLOGY

The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017

(2020) Longfei Lin et al.   Liver Cancer

Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis

(2019) Miao Lu et al.   BMC CANCER

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers

(2019) Flavia Fondevila et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling

(2019) Guoxu Fang et al.   CANCER LETTERS

Challenges in liver cancer and possible treatment approaches

(2019) David Anwanwan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Reprogramming of fatty acid metabolism in cancer

(2019) Nikos Koundouros et al.   BRITISH JOURNAL OF CANCER

The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases

(2019) Haojie Wang et al.   Cells

Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer

(2019) Camilla Evangelisti et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Overexpression of Forkhead Box O3a and Its Association With Aggressive Phenotypes and Poor Prognosis in Human Hepatocellular Carcinoma

(2018) Hyein Ahn et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

(2018) Richard S. Finn et al.   JOURNAL OF HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

(2018) Pegah Golabi et al.   MEDICINE

mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation

(2018) Long He et al.   MOLECULAR CELL

Autophagy as a promoter of longevity: insights from model organisms

(2018) Malene Hansen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

(2018) Melanie B. Thomas et al.   ONCOLOGY

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma

(2018) Venkatesh Kancherla et al.   Frontiers in Genetics

mTOR Pathways in Cancer and Autophagy

(2018) Mathieu Paquette et al.   Cancers

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention

(2018) Zhenqiu Liu et al.   JOURNAL OF HEPATOLOGY

Inhibition of the sterol regulatory element-binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in mice

(2017) Na Li et al.   HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Dual role of autophagy in hallmarks of cancer

(2017) Shikha Satendra Singh et al.   ONCOGENE

Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases

(2017) Romina Mancinelli et al.   Oxidative Medicine and Cellular Longevity

Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma

(2017) Sufang Yang et al.   Oncology Letters

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

(2017) et al.   JAMA Oncology

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

(2016) D. Koeberle et al.   ANNALS OF ONCOLOGY

Inhibition of cyclic AMP response element-directed transcription by decoy oligonucleotides enhances tumor-specific radiosensitivity

(2016) Serk In Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma

(2016) D Shneor et al.   CANCER GENE THERAPY

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   LANCET

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

Regulation of ER stress-induced autophagy by GSK3β-TIP60-ULK1 pathway

(2016) Tiejian Nie et al.   Cell Death & Disease

FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition

(2016) Tianxiu Dong et al.   Oncotarget

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

(2015) Eleonore Beurel et al.   PHARMACOLOGY & THERAPEUTICS

BRD4 is a novel therapeutic target for liver fibrosis

(2015) Ning Ding et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signal Transduction in Cancer

(2015) R. Sever et al.   Cold Spring Harbor Perspectives in Medicine

Akt: a new activation mechanism

(2014) Yuan Gao et al.   CELL RESEARCH

FoxO Proteins: Regulation and Molecular Targets in Liver Cancer

(2014) S. Carbajo-Pescador et al.   CURRENT MEDICINAL CHEMISTRY

SREBP-1 Has a Prognostic Role and Contributes to Invasion and Metastasis in Human Hepatocellular Carcinoma

(2014) Chao Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

(2014) Jennifer J. Knox et al.   INVESTIGATIONAL NEW DRUGS

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

(2014) Andrew X. Zhu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cyclic adenosine monophosphate-responsive element-binding protein activation predicts an unfavorable prognosis in patients with hepatocellular carcinoma

(2014) Zhiwei Li et al.   OncoTargets and Therapy

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Autophagy regulation by nutrient signaling

(2013) Ryan C Russell et al.   CELL RESEARCH

Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer

(2013) Jiayi Wang et al.   HEPATOLOGY

Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends

(2013) Matthias S. Matter et al.   JOURNAL OF HEPATOLOGY

PDK1 controls upstream PI3K expression and PIP3 generation

(2013) A M Dieterle et al.   ONCOGENE

Targeting the PI3K-AKT-mTOR signaling network in cancer

(2013) Khurum H. Khan et al.   Chinese Journal of Cancer

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

(2012) S.P. Choo et al.   EUROPEAN JOURNAL OF CANCER

Hepatitis B virus X protein modulates oncogene yes-associated protein by CREB to promote growth of hepatoma cells

(2012) Tao Zhang et al.   HEPATOLOGY

Interplay between FOXO, TOR, and Akt

(2011) Nissim Hay   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

(2011) Timothy R. Peterson et al.   CELL

Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways

(2011) Jessica L. Yecies et al.   Cell Metabolism

Metabolic regulation by p53

(2011) Oliver D. K. Maddocks et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks

(2011) S. Alers et al.   MOLECULAR AND CELLULAR BIOLOGY

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

(2011) Joungmok Kim et al.   NATURE CELL BIOLOGY

NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma

(2011) Tom Luedde et al.   Nature Reviews Gastroenterology & Hepatology

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Population-based risk factors and resource utilization for HCC: US perspective

(2010) A. Sanyal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma

(2010) M.C. Kew   PATHOLOGIE BIOLOGIE

NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy

(2009) Jian-Min Wu et al.   CANCER LETTERS

An Emerging Role of mTOR in Lipid Biosynthesis

(2009) Mathieu Laplante et al.   CURRENT BIOLOGY

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

(2008) Andrei V. Budanov et al.   CELL

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY

Diagnosis and Treatment of Hepatocellular Carcinoma

(2008) Hashem B. El-Serag et al.   GASTROENTEROLOGY

Akt-dependent regulation of NF- B is controlled by mTOR and Raptor in association with IKK

(2008) H. C. Dan et al.   GENES & DEVELOPMENT

Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling

(2008) M. P. DeYoung et al.   GENES & DEVELOPMENT

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K/Akt: getting it right matters

(2008) T F Franke   ONCOGENE